中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

2273 records (took 0.038 seconds)

    Compositions for treating allergic disorders using (-) cetirizine
    14.
    发明专利
    Compositions for treating allergic disorders using (-) cetirizine 审中-公开
    使用（ - ）CETIRIZINE治疗过敏性疾病的组合物

    公开(公告)号：JP2006036791A

    公开(公告)日：2006-02-09

    申请号：JP2005301318

    申请日：2005-10-17

    Applicant: Sepracor Inc ,  セプラコア インコーポレイテッド

    Inventor： GRAY NANCY M

    IPC: A61K31/495 ,  C07D241/04 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06 ,  A61P37/08 ,  C07D295/08

    CPC classification number: A61K31/495

    Abstract: PROBLEM TO BE SOLVED: To provide a composition for treating allergic diseases.
    SOLUTION: Optically pure (-) cetirizine is used for the treatment of seasonal and perennial allergic rhinitis in humans, while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine. The optically pure (-) isomer is also useful for the treatment of allergic asthma and chronic and physical urticaria. The (-) cetirizine is an eosinophilic chemotactic inhibitor, and is thereby useful for treating allergic asthma, seasonal allergic rhinitis, atopic dermatosis, some kinds of parasitic diseases, chronic obstructive pulmonary diseases, and other diseases related to eosinophilia such as specific gastrointestinal tract and urinary organ disorders.
    COPYRIGHT: (C)2006,JPO&NCIPI

    Abstract translation: 待解决的问题：提供治疗过敏性疾病的组合物。 解决方案：光学纯（ - ）西替利嗪用于治疗人类季节性和常年性过敏性鼻炎，同时避免与西替利嗪的外消旋混合物相关的副作用的伴随责任。 光学纯的（ - ）异构体也可用于治疗过敏性哮喘和慢性和身体性荨麻疹。 （ - ）西替利嗪是一种嗜酸粒细胞趋化性抑制剂，因此可用于治疗过敏性哮喘，季节性过敏性鼻炎，特应性皮肤病，某些寄生虫病，慢性阻塞性肺疾病和其他与嗜酸性粒细胞增多有关的疾病如特异性胃肠道和 泌尿器官功能障碍 版权所有（C）2006，JPO＆NCIPI

    METHOD FOR USING (R)-ISOFLURANE AND (R)-DESFLURANE AND COMPOSITION
    15.
    发明专利
    METHOD FOR USING (R)-ISOFLURANE AND (R)-DESFLURANE AND COMPOSITION 失效

    公开(公告)号：JPH05186338A

    公开(公告)日：1993-07-27

    申请号：JP31704691

    申请日：1991-11-29

    Applicant: SEPRACOR INC

    Inventor： JIEEMUSU DABURIYUU YANGU ,  SUTEIIBUN BURANDO

    IPC: A61K31/02 ,  A61K31/08 ,  A61P23/00 ,  A61P25/20 ,  A61P43/00

    Abstract: PURPOSE: To diminish adverse effects caused by a high dose of racemic isoflurane or desflurane which is an anesthetic for inducing and maintaining anesthesia and which is administered by inhalation. CONSTITUTION: This method of inducing and maintaining anesthesia comprises administering by inhalation to a warm blooded animal including a mammal in need of anesthesia an amount sufficient to induce and maintain anesthesia but insufficient to cause adverse effects, of (R)-isoflurane or (R)-desflurane substantially not containing (S)-stereoisomer, while diminishing the concomitant liability of adverse effects, such as hypoventilation, low blood pressure and arrhythmia, associated with the administration. The inhalation concentration of the anesthetic (R-isomer) administered for inducing the anesthesia is 0.5-5.0%, 0.5-2.0%, when nitrous oxide is simultaneously administered, or 0.5-3.5%, when oxygen is simultaneously administered. Since the (R)-isoflurane or (R)-desflurane exhibits the anesthetic activity in a lower concentration and at a lower dose than the corresponding racemic mixture, adverse effects are little.

Patent Agency Ranking